Flunisolide Nasal Solution, USP 0.025%, 25 mL bottles, Rx only, Manufactured for: Ingenus Pharmac...
FDA Drug Recall #D-0010-2023 — Class II — September 30, 2022
Recall Summary
| Recall Number | D-0010-2023 |
| Classification | Class II — Moderate risk |
| Date Initiated | September 30, 2022 |
| Status | Completed |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Ingenus Pharmaceuticals Llc |
| Location | Orlando, FL |
| Product Type | Drugs |
| Quantity | 6176 bottles |
Product Description
Flunisolide Nasal Solution, USP 0.025%, 25 mL bottles, Rx only, Manufactured for: Ingenus Pharmaceuticals, LLC Orlando, FL 32839-6408; NDC 50742-317-25 UPC 3 50742 31725 7
Reason for Recall
Out of specification for related substances (impurities).
Distribution Pattern
Nationwide within the United States
Lot / Code Information
Lot #: 22E040 Exp. 07/2023; 22F038 Exp. 08/2023
Other Recalls from Ingenus Pharmaceuticals Llc
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0374-2022 | Class II | Clobetasol Propionate Foam, 0.05%, packaged in ... | Jan 10, 2022 |
| D-0146-2020 | Class II | Leucovorin Calcium Injection, USP 500 mg*/50 mL... | Oct 9, 2019 |
| D-1058-2019 | Class III | Diclofenac Sodium Topical Solution, 1.5% w/w, 5... | Mar 18, 2019 |
| D-0890-2018 | Class II | Irinotecan Hydrochloride Injection, USP, 100 mg... | Jun 8, 2018 |
| D-0891-2018 | Class II | Irinotecan Hydrochloride Injection, USP, 40 mg/... | Jun 8, 2018 |
Frequently Asked Questions
Nitrosamines are probable human carcinogens — they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.